🍑 Novo Nordisk's peak form

A Delaware court ruled against Musk's record-breaking pay deal | Weight-loss drugs didn't slim down Novo Nordisk | [Finimize](   TOGETHER WITH   Hi {NAME}, here's what you need to know for February 1st in 3:14 minutes.   🎭 Real estate moguls, rare coin collectors, and sure, art thieves. Join us for [Investing Beyond Stocks And Bonds]( at 5pm UK time today, and find out how alternative assets can make for unorthodox success stories. [Grab your free ticket]( Today's big stories - Elon Musk’s record pay agreement was blocked by a Delaware judge, giving doomsayers longer to save for their tickets to Mars - ETFs tend to be cheap, but these global market ETFs are a bargain like no other – [Read Now]( - Weight-loss drugs transformed Danish drug giant Novo Nordisk's bottom... line Beware: Delaware [Beware: Delaware] What’s going on here? Elon Musk’s $56 billion pay deal was [canceled]( after a lengthy court battle in the state that the Tesla head honcho loves to hate. What does this mean? Elon Musk has many skills, including the ability to convert a legion of young men into loyal fans of oddly shaped trucks through the medium of podcasts. But clearly, winning over a court of law is not one of them. Musk was granted a $56 billion ten-year pay deal back in 2018, the biggest in the history of corporate America. There was just one problem: a disgruntled shareholder, with a whole nine Tesla shares to their name, who argued that investors in the firm weren’t given a big enough heads-up. On Tuesday, a Delaware judge agreed. So even though Musk argued that the money could fund humanity’s move to Mars when the Earth crumbles, the court canceled the record-breaking compensation. Why should I care? Zooming out: A win for one is a win for all. Investors in the US don’t usually kick up a fuss about how much company bosses are paid. Not that it has anything on Musk’s deal, mind you: that $56 billion was [six]( times what 2021’s 200 highest-paid executives made combined. See, big payouts tend to be made in the form of shares or share options, as Musk’s was. That incentivizes big bosses to drum up the share price, which only benefits everyday shareholders too. The bigger picture: “G” for “Greater good”. Media has lit up the “E” in “ESG” with eco-friendly LED lights. But while environmental considerations matter, especially if you’d rather save the planet than follow Musk into infinite space, the social and governance factors tend to be overlooked. Musk’s pay debacle could dust off the governance folder, though: independent committees should ensure that a CEO’s salary lines up with the value they deliver, and this latest ruling could turn that theory into more common practice. You might also like: [Earnings preview: here’s what matters for Amazon](. Copy to share story: [( 🙋 [Ask a question](mailto:questions@finimize.com?body=Ask us a question: Where are you writing from? Let us know and we'll mention it when we reply.&noapp=true&subject=Beware: Delaware&utm_campaign=daily-global-01-02-2024&utm_source=email) Analyst Take Cheap As Chips: These Are London’s Lowest-Fee Global Market ETFs [Cheap As Chips: These Are London’s Lowest-Fee Global Market ETFs]( One of the biggest benefits of investing with ETFs is that [they’re cheap](. And that’s [not by accident](: ETF providers have been in fierce competition to offer investors the lowest fees possible. But there are [a ton]( of these funds out there that can grant you access to global markets, so I decided to take a look at some of the cheapest ones listed on the London Stock Exchange (and available through interactive investor) to help you find the ones you want. That’s today’s Insight: [the global market ETFs you could pick up for a song](. [Read or listen to the Insight here]( SPONSORED BY IG Defense can be the best offense The UK’s FTSE 100 contains some specifically [defensive dividend stocks](. So if you’re looking to invest in companies that are more likely to keep making money during economic slumps, this could be [the place to look](. [FTSE 100 defensive companies]( aren’t just well-known in the UK, they boast business models that are designed to stay profitable even when the economy drags down whole industries. But not all dividend stocks are created equal. Investors should understand factors like dividend yield, dividend coverage ratio, payout ratio, and debt levels. You don’t need to get the spreadsheet out, though: IG has put together [a list of the FTSE 100 dividend stocks that are worth your attention this February](. DisclaimerYour capital is at risk. 69% of retail investor accounts lose money when trading spread bets and CFDs with this provider. You should consider whether you can afford to take the high risk of losing your money. [Find Out More]( When you support our sponsors, you support us. Thanks for that. All The Right Places [All The Right Places] What’s going on here? Novo Nordisk’s [profit]( put on weight last year, one of the few spots where the Danish weight-loss drug giant will accept a little extra bloating. What does this mean? Weight-loss drugs promise to keep our waistlines in check, and with nearly half of US adults already interested in trying the newly mainstream medication, it’s no wonder that the sector was one of last year’s biggest investing themes. Novo was a real standout: its Ozempic and Wegovy products flew off the pharmacists’ shelves especially quickly, making up 40% of the firm’s total sales. That meant Novo’s obesity care department made 150% more revenue than the year before, enough to secure expectation-beating results as a whole. Plus, with doctors expected to write scripts for Ozempic and Wegovy as if the Sackler family were looking over their shoulders, Novo’s predicting revenue that’s another 22% higher this year. Why should I care? Zooming out: Let’s get medical. Novo is now, ironically, Europe’s heftiest firm. Investors piled into the stock last year, won over by the sheer number of potential slimmers out there. More than [two-thirds]( of US adults are said to be overweight or obese, after all. On top of that, though, are the company’s claims that Wegovy could ease the symptoms of ailments like kidney and heart disease. If Novo can prove that, insurance companies will be more likely to cover the cost, making the medicines more accessible to the masses. The bigger picture: Patents are a virtue. Novo’s Swiss rival didn’t fare quite as well, reporting lower-than-expected sales and profit for last year and underwhelming predictions for this year. [Novartis]( pinned the blame on expiring patents on some of its biggest-selling medications. When they time out, rivals can launch competing versions for less, nabbing market share faster than you can get to the drugstore. That’s a timely reminder for investors: medical companies can’t get away with being one-hit wonders forever. You might also like: [Earnings preview: here’s what matters for Apple](. Copy to share story: [( 🙋 [Ask a question](mailto:questions@finimize.com?body=Ask us a question: Where are you writing from? Let us know and we'll mention it when we reply.&noapp=true&subject=All The Right Places&utm_campaign=daily-global-01-02-2024&utm_source=email) 💬 Quote of the day "If you aren't fired with enthusiasm, you will be fired with enthusiasm." – Vince Lombardi (an American football coach) [Tweet this]( SPONSORED BY BIOSTEM Go behind the cubicle curtains to see the future of medical innovation [Biostem (OTC:BSEM)]( is developing the world’s most effective regenerative medicine products. Yup, you read that right: the ability to heal humans with regenerated cells is no longer the stuff of sci-fi movies – and [BSEM’s recent results]( prove it. BSEM brought in $16 million of revenue last year, up 142% from the year before. And the fourth quarter alone pulled in $11.5 million, [an eye-watering increase of 1,351%]( from the same time in 2022. That’s mainly down to the launch and widespread medical use of AmnioWrap2, [BSEM’s innovative allograft]( – the term for transporting cells or tissue – that can treat a wide range of wounds. In the last two months, [three more industry leaders]( have joined BSEM’s board. Plus, the Center For Medicare Services has just established [national pricing for AmnioWrap2](, covering all 50 states. With that sort of momentum and revenue potential, it’s no surprise that Zacks Small Cap Research recently increased BSEM’s [stock price estimate]( to $9.25. [Check out the medical marvel.]( [Find Out More]( This content is for US investors only, if you are not a US investor please ignore this content. This content is a paid advertisement for BioStem (OTC:BSEM) from Sideways Frequency and Finimize. This is not Finimize editorial content. Finimize received a fixed fee for producing, hosting and promoting this content on behalf of BioStem (OTC:BSEM), totalling $12,000. Other than the compensation received for this service, Finimize and its principals are not affiliated with either Sideways Frequency or BioStem (OTC:BSEM). Finimize and its principals have no ownership in BioStem (OTC:BSEM). The content on this page should not be taken as advice, an endorsement, or a recommendation from Finimize and its principals to buy or sell any security. Finimize and its principals have not evaluated the accuracy of any claims made on this page. Finimize and its principals recommend that investors do their own independent research and consult with a qualified investment professional before buying or selling any security. Investing is inherently risky and capital is at risk. Past performance is not indicative of future results. When you support our sponsors, you support us. Thanks for that. 🎯 On Our Radar 1. Burn, baby, burn. Here’s how [burn-away reveal cakes](, trending on TikTok as we speak, actually work. 2. There's nothing like staying active. Here's how [different active investing strategies]( could play out for you.* 3. If you can’t love yourself… Dating is tough when you aren’t into yourself, but [it doesn’t need to be impossible](. 4. Time to take your first steps. Here's how to [get started on your investment journey](.** 5. This is a crisis. Future scientists will be baffled by the [underground tunnels]( hiding in the richest cities. **Your capital is at risk. 69% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you can afford to take the high risk of losing your money. When you support our sponsors, you support us. Thanks for that. SPONSORED BY HEALTHWORDS.AI [HEALTHWORDS.AI]( When you support our sponsors, you support us. Thanks for that. 🌍 Finimize Live 🤩 Coming Up Soon... All events in UK time. 📈 [Investing Beyond Stocks And Bonds](: 5pm, February 1st 💉 [The Rise of AI-Driven Healthcare Investments](: 5pm, February 13th 💰 [The Inevitable Future of Cryptocurrency](: 5pm, February 20th 🔮 [Future-Proof Your Portfolio With Artificial Intelligence](: 5pm, February 27th 🚀 [2024 Modern Investor Summit](: 2pm, December 3rd ❤️ Share with a friend Thanks for reading {NAME}. If you liked today's brief, we'd love for you to share it with a friend. You stay classy, {NAME} 😉 We’d love to hear your thoughts. [Give feedback]( Want to advertise with us too? [Get in touch]( Image Credits: Image credits: elon musk | fcm82 shutterstock Preferences: [Update your email]( or [change preferences]( [View in browser]( [Unsubscribe]( from all Finimize Emails 😴 Crafted by Finimize Ltd. | 280 Bishopsgate, London, EC2M 4AG All content provided by Finimize Ltd. is for informational and educational purposes only and is not meant to represent trade or investment recommendations. You signed up to this mailing list at finimize.com or through one of our partners. © Finimize 2021 [View Online](